Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cel-Sci Corp (CVM)

Cel-Sci Corp (CVM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 269,391
  • Shares Outstanding, K 34,805
  • Annual Sales, $ 480 K
  • Annual Income, $ -31,840 K
  • 60-Month Beta 2.98
  • Price/Sales 518.06
  • Price/Cash Flow N/A
  • Price/Book 225.27

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.02 +10.26%
on 11/14/19
8.25 -6.18%
on 11/20/19
+0.62 (+8.71%)
since 11/13/19
3-Month
6.00 +29.00%
on 10/24/19
9.93 -22.05%
on 09/27/19
-0.33 (-4.09%)
since 09/13/19
52-Week
2.37 +226.58%
on 03/01/19
9.93 -22.05%
on 09/27/19
+4.77 (+160.61%)
since 12/13/18

Most Recent Stories

More News
CEL-SCI Corporation to Present at The LD Micro Main Event (XII)

VIENNA, VA / ACCESSWIRE / December 6, 2019 / CEL-SCI Corporation (NYSE American:CVM), a Phase 3 cancer immunotherapy company, today announced that it will be presenting at the 12th annual LD Micro Main...

CVM : 7.74 (+1.04%)
CEL-SCI Corporation to Present at Dawson James Securities 5th Annual Small Cap Growth Conference

CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that Geert Kersten, Chief Executive Officer, will be presenting at the Dawson James Securities Small Cap...

CVM : 7.74 (+1.04%)
CEL-SCI Corporation Issues Letter to Shareholders

CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders.

CVM : 7.74 (+1.04%)
CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study

CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company's pivotal Phase 3 head and neck cancer study of its investigational immunotherapy...

CVM : 7.74 (+1.04%)
Biotechs Strive to Combat Rising Cancer Mortality Rates

FinancialBuzz.com News Commentary

ABT : 86.35 (+0.44%)
ABBV : 87.84 (-1.00%)
BMY : 63.82 (-0.19%)
CVM : 7.74 (+1.04%)
PBIO : 0.7400 (-2.63%)
Biotechs Strive to Combat Rising Cancer Mortality Rates

Cancer is a disease that involves the abnormal growth of cells which results in the formation of a tumor. The abnormal cells have a tendency to spread to other local tissues and may also spread to different...

PBIO : 0.7400 (-2.63%)
CVM : 7.74 (+1.04%)
ABBV : 87.84 (-1.00%)
BMY : 63.82 (-0.19%)
ABT : 86.35 (+0.44%)
CEL-SCI Corporation to Present at H.C. Wainwright 21st Annual Global Investment Conference

CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that Geert Kersten, Chief Executive Officer, is scheduled to present at the H.C. Wainwright 21st Annual...

CVM : 7.74 (+1.04%)
CEL-SCI Corporation Reports Third Quarter Fiscal 2019 Financial Results

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2019. The Company also reported key clinical and corporate developments achieved during the quarter....

CVM : 7.74 (+1.04%)
CEL-SCI's Scientific Review on Inflammatory Disease Therapies Published in Peer Reviewed Journal "International Immunopharmacology"

--

CVM : 7.74 (+1.04%)
CEL-SCI Collaborators Presents Data for New Vaccine in the Treatment of Rheumatoid Arthritis at the International Conference on Immunity and Immunochemistry Meeting

CEL-SCI Corporation (NYSE American: CVM) announced that one of its key collaborators from Rush University Medical center, Dr. Adrienn Markovitz an Assistant professor in the department of Orthopedic Surgery,...

CVM : 7.74 (+1.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade CVM with:

Business Summary

CEL-SCI CORP. was formed to acquire and finance research and development of natural human interleukin-2 (``IL-2``) and lymphokine-related products and processes using the Co.'s proprietary cell culture technologies. The Co.'s proprietary product is sometimes referred to as MULTIKINEn, or buffy-coat interleukins,...

See More

Key Turning Points

2nd Resistance Point 7.89
1st Resistance Point 7.82
Last Price 7.74
1st Support Level 7.59
2nd Support Level 7.43

See More

52-Week High 9.93
Last Price 7.74
Fibonacci 61.8% 7.04
Fibonacci 50% 6.15
Fibonacci 38.2% 5.26
52-Week Low 2.37

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar